Scholarlink

Introduction <p>Coexisting type&#xa0;2 inflammatory diseases such as allergic rhinitis (AR), atopic dermatitis (AD), chronic rhinosinusitis (CRS) and/or nasal polyposis (NP), eosinophilic esophagitis (EoE), and urticaria are common in asthma. RAPID (NCT04287621), a global prospective registry, aimed to characterize patients with asthma initiating dupilumab in a real-world clinical setting. This analysis investigated the prevalence of coexisting type&#xa0;2 inflammatory diseases in these patients.</p> Methods <p>Patients aged ≥ 12&#xa0;years initiating dupilumab for asthma (primary indication) according to country-specific prescribing information were enrolled in RAPID. Patients had regular assessments at 1&#xa0;month and thereafter every 3&#xa0;months for up to 3&#xa0;years, per standard of care across study sites.</p> Results <p>At the time of analysis, 205 patients were enrolled. Mean age of patients (stratified by type&#xa0;2 coexisting disease) ranged from 42.3 to 57.3&#xa0;years and mean body mass index from 29.9 to 31.8&#xa0;kg/m<sup>2</sup>. Most patients were female (67.3% to 77.4%), and mean time since asthma diagnosis was 17.3 to 24.0&#xa0;years, with mean duration of coexisting diseases ranging from 9.8 to 17.0&#xa0;years. A total of 189 (92%) patients had ≥ 1 ongoing type&#xa0;2 coexisting disease (AR, 80%; CRS and/or NP, 45% [CRS with NP, 47%; CRS without NP, 41%; NP, 12%]; AD, 27%; urticaria, 15%; and EoE, 3%).</p> Conclusion <p>This analysis from the RAPID registry shows that type&#xa0;2 coexisting diseases are highly prevalent in patients with asthma initiating dupilumab in a clinical practice setting and highlights the importance of properly assessing patients to improve patient care.</p> Trial Registration <p>ClinicalTrials.gov: NCT04287621.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Coexisting Type 2 Inflammatory Conditions in Patients with Asthma Treated with Dupilumab: the RAPID Registry

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月30日

查看全文
  • Anju T. Peters,
  • Andréanne Côté,
  • Xavier Muñoz,
  • Changming Xia,
  • Scott Nash,
  • Megan Hardin,
  • Lucía de Prado Gómez,
  • Harry J. Sacks,
  • Juby A. Jacob-Nara,
  • Paul J. Rowe,
  • Yamo Deniz

摘要

Introduction

Coexisting type 2 inflammatory diseases such as allergic rhinitis (AR), atopic dermatitis (AD), chronic rhinosinusitis (CRS) and/or nasal polyposis (NP), eosinophilic esophagitis (EoE), and urticaria are common in asthma. RAPID (NCT04287621), a global prospective registry, aimed to characterize patients with asthma initiating dupilumab in a real-world clinical setting. This analysis investigated the prevalence of coexisting type 2 inflammatory diseases in these patients.

Methods

Patients aged ≥ 12 years initiating dupilumab for asthma (primary indication) according to country-specific prescribing information were enrolled in RAPID. Patients had regular assessments at 1 month and thereafter every 3 months for up to 3 years, per standard of care across study sites.

Results

At the time of analysis, 205 patients were enrolled. Mean age of patients (stratified by type 2 coexisting disease) ranged from 42.3 to 57.3 years and mean body mass index from 29.9 to 31.8 kg/m2. Most patients were female (67.3% to 77.4%), and mean time since asthma diagnosis was 17.3 to 24.0 years, with mean duration of coexisting diseases ranging from 9.8 to 17.0 years. A total of 189 (92%) patients had ≥ 1 ongoing type 2 coexisting disease (AR, 80%; CRS and/or NP, 45% [CRS with NP, 47%; CRS without NP, 41%; NP, 12%]; AD, 27%; urticaria, 15%; and EoE, 3%).

Conclusion

This analysis from the RAPID registry shows that type 2 coexisting diseases are highly prevalent in patients with asthma initiating dupilumab in a clinical practice setting and highlights the importance of properly assessing patients to improve patient care.

Trial Registration

ClinicalTrials.gov: NCT04287621.